These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32405660)

  • 1. Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?
    Wu JP; Peng L; Zeng X; Li H; Shen H; Luo DY
    Int Urogynecol J; 2021 May; 32(5):1117-1127. PubMed ID: 32405660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
    Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
    Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
    Huang W; Zong H; Zhou X; Zhang Y
    Int Urol Nephrol; 2015 Mar; 47(3):457-64. PubMed ID: 25636812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi O;
    Int J Urol; 2009 May; 16(5):499-506. PubMed ID: 19389083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
    Yang N; Wu Q; Xu F; Zhang X
    J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
    Park C; Park J; Choo MS; Kim JC; Lee JG; Lee JZ; Lee KS; Kim DY; Lee SJ; Seo JT
    Int J Clin Pract; 2014 Feb; 68(2):188-96. PubMed ID: 24373019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
    Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
    Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).
    Otsuka A; Kageyama S; Suzuki T; Matsumoto R; Nagae H; Kitagawa M; Furuse H; Ozono S
    Int J Urol; 2016 Dec; 23(12):1016-1023. PubMed ID: 27686226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder.
    Wada N; Watanabe M; Kita M; Matsumoto S; Osanai H; Yamaguchi S; Numata A; Fujisawa M; Saga Y; Hou K; Iuchi H; Niibori D; Kura T; Taniguchi A; Kunieda M; Nakata Y; Kakizaki H
    Urol Int; 2012; 89(2):215-21. PubMed ID: 22832092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan.
    Chuang YC; Lin CC; Chow PM; Lien CS; Tsui KH; Chou CL; Lee HY; Meng E; Kuo HC
    Low Urin Tract Symptoms; 2021 Jan; 13(1):108-117. PubMed ID: 32844599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
    Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
    Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
    De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
    Eur Urol; 2021 Apr; 79(4):492-504. PubMed ID: 33402296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Mostafaei H; Salehi-Pourmehr H; Jilch S; Carlin GL; Mori K; Quhal F; Pradere B; Grossmann NC; Laukhtina E; Schuettfort VM; Aydh A; Sari Motlagh R; König F; Roehrborn CG; Katayama S; Rajwa P; Hajebrahimi S; Shariat SF
    Eur Urol Focus; 2022 Jul; 8(4):1072-1089. PubMed ID: 34563481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imidafenacin for treatment of overactive bladder and urgent urinary incontinence: the results of open-label multicenter randomized controlled clinical trial].
    Al-Shukri SH; Pushkar DY; Apolikhin OI; Evdokimov MS; Kogan MI; Krivoborodov GG; Kagan OF; Petrov SB; Poltoratskyi AN; Kuzmin IV; Sharvadze GG
    Urologiia; 2018 Dec; (6):20-25. PubMed ID: 30742373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder.
    Lee KS; Park B; Kim JH; Kim HG; Seo JT; Lee JG; Jang Y; Choo MS
    Int J Clin Pract; 2013 Dec; 67(12):1317-26. PubMed ID: 24246210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.